OTC Pain Management-US-July 2019: Hemp-Derived CBD Forays In the Mainstream Drug

Posted by Deeksha on August 21st, 2019

Majority of Americans have innate inclination towards over-the-counter (OTC) analgesics for ephemeral relief of mild-to-moderate pain. In light of prevalent use of OTC analgesics among consumers and the increased level of consumer trust in these agents, clinicians and stakeholders are profoundly discussing OTC analgesic use with the patients. These insights are according to the intelligence report, titled, “OTC Pain Management-US-July 2019,” which has been freshly added to Market Research Hub’s (MRH) ever-expanding armamentarium. Amid increase in drug overdose deaths involving opioids, several companies are heavily investing in developing abuse-deterrent opioid drugs that will potentially reduce the abuse and addiction. Nevertheless, the FDA is painstakingly working to offer more stringent industry guidelines on the approval of opioid pain drugs.

Check for the sample here @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2461293

Cannabidiol (CBD) and cannabis have been the cynosure of eyes in OTC pain management in the U.S. as hemp-derived CBD forays in the mainstream drug stores and legalization of cannabis grabs attention. CBD accessibility is expected to bring paradigm shift in OTC pain management market.

With CBD being touted for a myriad of health issues, it has gained traction for its sheer impact in treating a few of the childhood epilepsy syndromes, including Lennox-Gastaut syndrome and Dravet syndrome that generally remain unflustered to antiseizure medications. Of late, FDA approved the first of its kind cannabis-derived medicine containing CBD.

While there has been increased traction for the use of oral OTC pain relievers with adults, young consumers have inclination towards natural pain relief. However, high cost and dearth of innovation may dent the growth of OTC pain management.

Request TOC of the Report @ https://www.marketresearchhub.com/report/otc-pain-management-us-july-2019-report.html

OTC Pain Management—US—July 2019: Report Content

Quantitative and qualitative assessment exhort intelligence and overarching report on the OTC pain management—US—July 2019 market. Further, the report thoroughly delineates various aspects of the market that will potentially have considerable influence on the development of the OTC pain management—US—July 2019 market. As such, those aspects incorporate drivers, trends, restraints, and opportunities. Furthermore, the report elucidates segregation of the market that provides an exhaustive analysis on OTC pain management—US—July 2019.

An insightful and deep-dive assessment of the competitive assessment of the OTC pain management—US—July 2019 market pins hope on Porters’ Five Force Analysis. Accordingly, the Porters’ Five Force Analysis offers a pressing analysis on the potential strategies of the preeminent players in the OTC pain management—US—July 2019 market. In addition, the business strategies counts on company overview, product portfolio, SWOT analysis, key differentiation and recent development.

OTC Pain Management—US—July 2019: Research Methodology

Primary sources and secondary sources propel intelligence report on OTC pain management—US—July 2019 market that provide deep dive analysis on the market. As such, the report provides reliable and unbiased projections, and assessments which have palpable impact on the market size and historical data. Besides, the report also counts on primary sources which hinges upon in-depth and intelligent analysis from well-grounded and reliable experts, telephonic interview, and a thorough assessment from surveys and seasoned analyst. Report on OTC pain management—US—July 2019 market further acknowledges secondary sources—namely—Factiva, EC filing, press release, trade journals, resourceful database and governmental websites.